Last reviewed · How we verify
Caribou-sponsored investigational therapy — Competitive Intelligence Brief
phase 2
CRISPR-Cas12 system
Genetics, Gene Therapy
Biologic
Live · refreshed every 30 min
Target snapshot
Caribou-sponsored investigational therapy (Caribou-sponsored investigational therapy) — Caribou Biosciences, Inc.. This investigational therapy targets the CRISPR-Cas12 system to modulate gene expression.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Caribou-sponsored investigational therapy TARGET | Caribou-sponsored investigational therapy | Caribou Biosciences, Inc. | phase 2 | CRISPR-Cas12 system |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Caribou-sponsored investigational therapy CI watch — RSS
- Caribou-sponsored investigational therapy CI watch — Atom
- Caribou-sponsored investigational therapy CI watch — JSON
- Caribou-sponsored investigational therapy alone — RSS
Cite this brief
Drug Landscape (2026). Caribou-sponsored investigational therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/caribou-sponsored-investigational-therapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab